Pharmaceutical

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated…

4 months ago

Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer

HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of…

4 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September…

4 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed…

4 months ago

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

4 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer’s disease Cognitive outcomes observed in the…

4 months ago

Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference

Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the…

4 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa.,…

4 months ago

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors

Veteran life sciences industry financing leader appointed as new Board memberHOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience,…

4 months ago